Cardiff Oncology
CRDF
55 hedge funds and large institutions have $7.58M invested in Cardiff Oncology in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 4 closing their positions.
337% more call options, than puts
Call options by funds: $363K | Put options by funds: $83K
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
4% more funds holding
Funds holding: 53 → 55 (+2)
1.36% less ownership
Funds ownership: 13.41% → 12.05% (-1.4%)
14% less capital invested
Capital invested by funds: $8.81M → $7.58M (-$1.22M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$379K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$33.7K |
| 3 |
CC
Callan Capital
La Jolla,
California
|
+$29.6K |
| 4 |
JP Morgan Chase
New York
|
+$29.6K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$457K |
| 2 |
Renaissance Technologies
New York
|
-$265K |
| 3 |
Two Sigma Advisers
New York
|
-$222K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$145K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$98.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $88 | -$6.33K | -3,751 | -98% |
|
52
Qube Research & Technologies (QRT)
London,
United Kingdom
| $72 | +$88 | +52 | New |
|
53
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $67 | – | – | – |
|
|
CPG
54
Cornerstone Planning Group
Fairfield,
New Jersey
| $7 | +$8 | +5 | New |
|
|
FRA
55
Front Row Advisors
Tiburon,
California
| $3 | – | – | – |
|
|
56
Citadel Advisors
Miami,
Florida
| – | -$145K | -86,123 | Closed |
|
57
Millennium Management
New York
| – | -$71.6K | -48,739 | Closed |
|
58
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$32.1K | -19,007 | -98% |
|
|
NC
59
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$184 | -125 | Closed |
|
|
FGAM
60
Financial Gravity Asset Management
Lakeway,
Texas
| – | -$2 | -1 | Closed |
|
CRDF Hedge Fund Activity: Q3 2023 in Review
55 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2023, worth a combined $7.58M — down 14% from $8.81M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRDF positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 15 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $379K. The largest seller was GSA Capital Partners, cutting an estimated $457K.
- 55 institutional investors held Cardiff Oncology (CRDF) as of Q3 2023, up from 53 in Q2 2023.
- Funds reported $7.58M of Cardiff Oncology stock for Q3 2023, down 14% quarter-over-quarter.
- 7 funds opened new Cardiff Oncology positions in Q3 2023 and 4 closed out, a net change of +3 holders.
- The largest Cardiff Oncology buyer in Q3 2023 was MAI Capital Management, an estimated $379K added.
- The largest Cardiff Oncology seller in Q3 2023 was GSA Capital Partners, an estimated $457K sold.
Based on aggregated 13F filings for Q3 2023.